GS treatment of HNSCC cells prevents NF-κB activation and leads to its degradation resulting in the inhibition of inflammatory and angiogenic responses as well as progression and metastasis [35, 36]. Here, NFKB1 is linked to head and neck squamous cell carcinoma.